Jpmorgan Chase & CO Xeris Biopharma Holdings, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,114,709 shares of XERS stock, worth $10.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,114,709
Previous 1,043,441 102.67%
Holding current value
$10.3 Million
Previous $3.54 Million 228.22%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$3.2 - $5.95 $3.43 Million - $6.37 Million
1,071,268 Added 102.67%
2,114,709 $11.6 Million
Q4 2024

Feb 12, 2025
BUY
$2.78 - $3.73 $1.81 Million - $2.43 Million
651,481 Added 166.21%
1,043,441 $3.54 Million
Q3 2024

Dec 26, 2024
BUY
$2.06 - $2.96 $139,167 - $199,968
67,557 Added 20.83%
391,960 $1.12 Million
Q3 2024

Nov 08, 2024
BUY
$2.06 - $2.96 $139,167 - $199,968
67,557 Added 20.83%
391,960 $1.12 Million
Q2 2024

Dec 26, 2024
SELL
$1.7 - $2.45 $114,846 - $165,514
-67,557 Reduced 17.24%
324,403 $729,000
Q2 2024

Aug 12, 2024
SELL
$1.7 - $2.45 $84,918 - $122,382
-49,952 Reduced 13.34%
324,403 $729,000
Q1 2024

Dec 26, 2024
SELL
$2.04 - $3.22 $35,914 - $56,688
-17,605 Reduced 4.49%
374,355 $827,000
Q1 2024

May 10, 2024
BUY
$2.04 - $3.22 $105,914 - $167,179
51,919 Added 16.1%
374,355 $827,000
Q4 2023

Dec 26, 2024
SELL
$1.47 - $2.36 $102,200 - $164,076
-69,524 Reduced 17.74%
322,436 $757,000
Q4 2023

Feb 12, 2024
BUY
$1.47 - $2.36 $302,055 - $484,932
205,480 Added 175.69%
322,436 $757,000
Q3 2023

Nov 14, 2023
SELL
$1.8 - $2.69 $333,720 - $498,726
-185,400 Reduced 61.32%
116,956 $217,000
Q2 2023

Aug 11, 2023
SELL
$1.82 - $2.98 $844,361 - $1.38 Million
-463,935 Reduced 60.54%
302,356 $792,000
Q1 2023

May 18, 2023
BUY
$1.03 - $1.63 $104,466 - $165,321
101,424 Added 15.25%
766,291 $1.25 Million
Q1 2023

May 11, 2023
BUY
$1.03 - $1.63 $587,562 - $929,831
570,449 Added 604.17%
664,867 $1.08 Million
Q4 2022

Feb 13, 2023
BUY
$1.14 - $1.65 $11,509 - $16,658
10,096 Added 11.97%
94,418 $126,000
Q3 2022

Nov 14, 2022
BUY
$1.37 - $1.93 $6,455 - $9,094
4,712 Added 5.92%
84,322 $132,000
Q2 2022

Aug 11, 2022
BUY
$1.48 - $2.64 $90,213 - $160,921
60,955 Added 326.75%
79,610 $123,000
Q1 2022

May 11, 2022
BUY
$2.0 - $2.87 $10,796 - $15,492
5,398 Added 40.72%
18,655 $48,000
Q4 2021

Feb 10, 2022
BUY
$1.8 - $2.93 $23,862 - $38,843
13,257 New
13,257 $39,000

Others Institutions Holding XERS

# of Institutions
204
Shares Held
84.7M
Call Options Held
132K
Put Options Held
69.4K
View Full List

About Xeris Biopharma Holdings, Inc.

XERS Quotes by TradingView
  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $659M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email